BG Medicine (BGMD) Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
5/13/2013 9:38:36 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WALTHAM, Mass., May 10, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, announced today that the company granted a stock option to Paul Sohmer, M.D., the company's newly appointed President and Chief Executive Officer, on May 10, 2013. The stock option was granted as an inducement material to Dr. Sohmer's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), which, under these circumstances, provides an exception to the stockholder approval requirements and allows for the grant of this stock option to be made outside the company's stockholder-approved equity plans.
Help employers find you! Check out all the jobs and post your resume.
comments powered by